India Orders Cough-Syrup Maker Linked to Cameroon Deaths to Halt Production
(Bloomberg) -- Indian authorities ordered a cough syrup manufacturer linked to the deaths of a dozen children in Cameroon to stop production, the latest drugmaker the country has taken action against after a spate of tainted medical exports.
The government of the central state of Madhya Pradesh “directed” Indore-based Riemann Labs Pvt. Ltd. to halt manufacturing following a joint inspection by the country's central and state-level drug regulators, Deputy Health Minister Bharati Pravin Pawar told lawmakers in New Delhi on Tuesday.
A phone number listed on Riemann Lab's website was switched off and the company didn't immediately respond to an emailed request for comment.
The inspection of Riemann Lab's came after Bloomberg News reported that Cameroonian officials suspected a batch of Naturcold, showing a manufacturing license number matching Riemann Labs, of having caused the death of a dozen children. It was the third set of fatalities associated with contaminated Indian cough syrup in a year, putting country's $50 billion drug-making industry under heightened scrutiny. The others were in Gambia and Uzbekistan.
Read more: WHO Says Kid Syrup Linked to Cameroon Deaths Had Toxic Chemical
A director at Riemann told Bloomberg News in June that the medicine, which appeared in a photo obtained from Cameroonian health officials, “looked like” the firm's products. However, they said that Riemann followed strict quality controls and that counterfeiting is common. The World Health Organization last month said it had more than 200 times the acceptable amount of toxic diethylene glycol.
Pawar didn't name the cough syrup sold by Riemann in Cameroon, but noted that authorities have halted production and suspended licenses of three other drugmakers following WHO alerts over tainted cough medicine.
Since June, India has also made it compulsory for cough-syrup makers to send samples to a government-approved laboratory and obtain a certificate of analysis before their products can be exported.
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
